Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;13(9):2093-2105.
doi: 10.1007/s13555-023-00986-0. Epub 2023 Aug 5.

The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis

Affiliations

The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis

Alessandra Buja et al. Dermatol Ther (Heidelb). 2023 Sep.

Abstract

Introduction: Psoriasis (PsO) is currently regarded as a systemic inflammatory disease with a growing burden of post-diagnosis associated comorbidities. To determine the initial burden of comorbiditis we evaluated the comorbidome at PsO onset.

Methods: In a matched case-control study, we extracted data on 57,228 patients and 125 morbidities from the Clalit Health Services Israeli insurance database. PsO cases were matched with control individuals by sex and age at enrolment. As pre-existing comorbidities, we considered all conditions already present in controls at the same age as the matched PsO case at the time of their diagnosis. To test for differences in the odds of comorbidities between the case and control groups, logistic regression analyses were run to calculate the odds ratio (OR) for each comorbidity, after which the comorbidome was graphically represented.

Results: In this study we enrolled 28,614 PsO patients and 28,614 controls with an average age of 45.3 ± 19.6 years. At the time of diagnosis, PsO patients were more likely to be diagnosed with 2-4 comorbidities (28.8% vs 23.8%) and > 5 (19.6% vs 12.9%,). PsO patients' specific comorbidomes evidenced several pathological cores: autoimmune and inflammatory systemic diseases [i.e., hidradenitis suppurativa (OR 3.55, 95% CI 1.88-7.28) or polymyalgia rheumatica (OR 3.01 95% CI 1.96-4.77)], inflammatory bowel diseases [i.e., Crohn's disease (OR 2.99 95% CI 2.20-4.13)], pulmonary inflammatory diseases [i.e., chronic obstructive pulmonary disease (OR 1.81 95% CI 1.61-2.04)], hepatological diseases [i.e., cirrhosis (OR 2.00 95% CI 1.36-3.00)], endocrine diseases [dysthyroidisms (OR 1.82 95% CI 1.30-2.59)], mental disorders [i.e., depression (OR 1.72 95% CI 1.57-1.87)], and cardiovascular diseases (i.e., hypertension (OR 1.47 95% CI 1.41-1.53)].

Conclusion: The PsO-onset comorbidome may help health professionals plan more comprehensive patient management. By screening for these common PsO-linked conditions, early diagnosis and treatment may become more frequent, thus greatly benefiting patients on their medical journey.

Keywords: Comorbidome; Precision medicine; Psoriasis; Systemic inflammation; Treatment.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
The PsO comorbidome. The size of each bubble is proportional to the prevalence of the disease. The proximity to the center expresses instead the strength of the association between the morbidity and the PsO diagnosis and is the inverse of the OR. The dashed orbit corresponds to a radius OR = 1. All circles relating to a disease with an increased occurrence among the psoriatic group fall inside that orbit (1/OR < 1); vice versa, morbidities with a decreased prevalence are outside (1/OR > 1)

References

    1. Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The Global, Regional, and National Burden of PsO: results and insights from the global burden of disease 2019 study. Front Med. 2021 doi: 10.3389/fmed.2021.743180. - DOI - PMC - PubMed
    1. Takeshita J, Grewal S, Langan SM, et al. PsO and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76:377–390. doi: 10.1016/j.jaad.2016.07.064. - DOI - PMC - PubMed
    1. Kamiya K, Kishimoto M, Sugai J, et al. Risk factors for the development of PsO. Int J Mol Sci. 2019;20:4347. doi: 10.3390/ijms20184347. - DOI - PMC - PubMed
    1. Lee Y, Nam Y-H, Lee J-H, et al. Hypocalcaemia-induced pustular PsO-like skin eruption. Br J Dermatol. 2005;152:591–593. doi: 10.1111/j.1365-2133.2005.06460.x. - DOI - PubMed
    1. Bu J, Ding R, Zhou L, et al. Epidemiology of PsO and comorbid diseases: a narrative review. Front Immunol. 2022;13:880201. doi: 10.3389/fimmu.2022.880201. - DOI - PMC - PubMed